383 related articles for article (PubMed ID: 25236350)
1. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
[TBL] [Abstract][Full Text] [Related]
2. 111In-cetuximab-F(ab')2 SPECT and 18F-FDG PET for prediction and response monitoring of combined-modality treatment of human head and neck carcinomas in a mouse model.
van Dijk LK; Boerman OC; Franssen GM; Kaanders JH; Bussink J
J Nucl Med; 2015 Feb; 56(2):287-92. PubMed ID: 25552666
[TBL] [Abstract][Full Text] [Related]
3. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
4. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
[TBL] [Abstract][Full Text] [Related]
5. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
[TBL] [Abstract][Full Text] [Related]
6. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
8. Preclinical validation of
Huizing FJ; Hoeben BAW; Franssen G; Lok J; Heskamp S; Oosterwijk E; Boerman OC; Bussink J
Radiother Oncol; 2017 Sep; 124(3):521-525. PubMed ID: 28789809
[TBL] [Abstract][Full Text] [Related]
9. A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck.
Adkins D; Ley J; Dehdashti F; Siegel MJ; Wildes TM; Michel L; Trinkaus K; Siegel BA
Cancer Med; 2014 Dec; 3(6):1493-501. PubMed ID: 25081631
[TBL] [Abstract][Full Text] [Related]
10. 18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.
Hoeben BA; Troost EG; Bussink J; van Herpen CM; Oyen WJ; Kaanders JH
Nuklearmedizin; 2014; 53(2):60-6. PubMed ID: 24468965
[TBL] [Abstract][Full Text] [Related]
11. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
[TBL] [Abstract][Full Text] [Related]
12. Detailed characterization of the early response of head-neck cancer xenografts to irradiation using (18)F-FDG-PET imaging.
Huang J; Chunta JL; Amin M; Lee DY; Grills IS; Wong CY; Yan D; Marples B; Martinez AA; Wilson GD
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):485-91. PubMed ID: 22331000
[TBL] [Abstract][Full Text] [Related]
13. Imaging integrin αvβ3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts.
Terry SY; Abiraj K; Frielink C; van Dijk LK; Bussink J; Oyen WJ; Boerman OC
J Nucl Med; 2014 Feb; 55(2):281-6. PubMed ID: 24408894
[TBL] [Abstract][Full Text] [Related]
14. Noninvasive Evaluation of EGFR Expression of Digestive Tumors Using
Shi D; Zhang Y; Xu Z; Si Z; Cheng Y; Cheng D; Liu G
Mol Imaging; 2022; 2022():3748315. PubMed ID: 35903247
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models.
Huizing FJ; Hoeben BAW; Franssen GM; Boerman OC; Heskamp S; Bussink J
Mol Pharm; 2019 Feb; 16(2):701-708. PubMed ID: 30550290
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
[TBL] [Abstract][Full Text] [Related]
17. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
18. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
19. Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
Terry SY; Abiraj K; Lok J; Gerrits D; Franssen GM; Oyen WJ; Boerman OC
J Nucl Med; 2014 Nov; 55(11):1849-55. PubMed ID: 25349221
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism.
Li LF; Zhou SH; Zhao K; Wang SQ; Wu QL; Fan J; Cheng KJ; Ling L
Cancer Biother Radiopharm; 2008 Dec; 23(6):701-14. PubMed ID: 19317609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]